Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-03-27Clinical Trial Update: MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine [Phase 1, Phase 2]
Phase 1/2 trial update of alisertib (MLN8237) in relapsed or refractory aggressive B-cell lymphomas treated with rituximab with or without v…
-
CLINICAL_TRIALS trial_result · 2018-03-19Clinical Trial Update: Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas [Phase 2]
Phase 2 clinical trial update on peptide receptor radionuclide therapy with yttrium-90 DOTATOC in relapsed/refractory diffuse large B-cell l…
-
CLINICAL_TRIALS trial_result · 2018-03-12Clinical Trial Update: Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. [Phase 1, Phase 2]
This completed Phase 1/2 study evaluated a combination of lenalidomide, bendamustine, and rituximab as first-line therapy in patients over 6…
-
CLINICAL_TRIALS trial_result · 2018-03-09Clinical Trial Update: Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL [Phase 2]
Phase 2 study evaluating bendamustine, lenalidomide, and rituximab as second-line therapy for first-relapsed/refractory mantle cell lymphoma…
-
CLINICAL_TRIALS trial_result · 2018-03-06Clinical Trial Update: Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating vorinostat in multiple low-grade non-Hodgkin lymphomas, including MALT lymphoma, nodal marginal zone lymphoma, foll…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2018-02-16FDA Approved: IMBRUVICA — Original Application (Pharmacyclics LLC)
FDA approved IMBRUVICA (ibrutinib) under the Original Application (NDA210563) for mantle cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2018-02-09Clinical Trial Update: Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients [Phase 3]
A Phase III randomized trial comparing lenalidomide versus observation after induction with rituximab followed by chemotherapy and autologou…
-
FDA approval · 2018-01-26FDA Approved: ZYDELIG — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for ZYDELIG (idelalisib) by Gilead Sciences, Inc.
-
CLINICAL_TRIALS trial_result · 2017-12-19Clinical Trial Update: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma [Phase 3]
Phase 3 clinical trial evaluating autologous stem cell transplant after a rituximab/ibrutinib/arac-containing induction in generalized mantl…
-
CLINICAL_TRIALS withdrawal · 2017-12-02Clinical Trial Update: T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies [Phase 1, Phase 2]
A trial investigating T-regulatory cell and CD3-depleted double umbilical cord blood transplantation for hematologic malignancies has been w…
-
CLINICAL_TRIALS trial_result · 2017-11-28Clinical Trial Update: Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD [Phase 2]
Phase 2 trial evaluating rituximab as prophylaxis to prevent chronic graft-versus-host disease after allogeneic stem cell transplantation; t…
-
CLINICAL_TRIALS trial_result · 2017-11-13Clinical Trial Update: Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma [Phase 2]
This Phase 2 trial evaluated the combination of vorinostat, cladribine, and rituximab in patients with mantle cell lymphoma, relapsed chroni…
-
FDA approval · 2017-10-31FDA Approved: CALQUENCE — Original Application (AstraZeneca Pharmaceuticals LP)
FDA approved CALQUENCE (acalabrutinib) from the original application by AstraZeneca Pharmaceuticals LP. This marks the initial approval of a…
-
CLINICAL_TRIALS trial_result · 2017-10-30Clinical Trial Update: Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL [Phase 2]
Phase 2 study of the R-GemOx regimen (rituximab, gemcitabine, and oxaliplatin) evaluating efficacy and tolerance in diffuse large B-cell lym…
-
CLINICAL_TRIALS trial_result · 2017-10-20Clinical Trial Update: Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma [Phase 2]
Phase 2 trial evaluating Bevacizumab combined with CHOP and Rituximab as first-line therapy for untreated mantle cell lymphoma; results were…
-
CLINICAL_TRIALS trial_result · 2017-10-19Clinical Trial Update: A Safety Study of SGN-CD19A for B-Cell Lymphoma [Phase 1]
Phase 1 safety study of SGN-CD19A in various B-cell lymphomas has completed; the update summarizes safety results across multiple indication…
-
CLINICAL_TRIALS trial_result · 2017-09-12Clinical Trial Update: Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma [Phase 2]
A Phase II clinical trial evaluating the RT-PEPC regimen in relapsed mantle cell lymphoma has completed, with results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-09-11Clinical Trial Update: Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating temsirolimus with bendamustine and rituximab in relapsed follicular lymphoma or mantle cell lymphoma has been com…
-
CLINICAL_TRIALS research · 2017-08-29Clinical Trial Update: Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0
This clinical trial update reports on blood immunophenotyping techniques to aid staging of indolent B-cell lymphomas, including Follicular L…
-
CLINICAL_TRIALS trial_result · 2017-08-07Clinical Trial Update: Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011) [Phase 1]
A Phase 1 trial update discusses the combination of bortezomib, cladribine, and rituximab (VCR) for Mantle Cell Lymphoma.
-
CLINICAL_TRIALS research · 2017-07-19Clinical Trial Update: Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia [Phase 1, Phase 2]
Clinical trial update describing a Phase 1/Phase 2 study of CT-1530 in relapsed or refractory B-cell non-Hodgkin lymphoma, chronic lymphocyt…
-
CLINICAL_TRIALS trial_result · 2017-06-29Clinical Trial Update: Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies [Phase 2]
A Phase 2 trial evaluating a combination of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with previously treated lymph…
-
FDA approval · 2017-06-09FDA Approved: VELCADE — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for Velcade (bortezomib) filed by Takeda Pharmaceuticals America, Inc., expanding or modifying i…
-
CLINICAL_TRIALS trial_result · 2017-06-07Clinical Trial Update: S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma [Phase 2]
Phase 2 trial investigating rituximab with combination chemotherapy or bendamustine followed by consolidation and stem cell transplantation …
-
CLINICAL_TRIALS trial_result · 2017-05-25Clinical Trial Update: Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating a combination of vorinostat, rituximab, ifosfamide, carboplatin, and etoposide in adults with relapsed/refracto…